Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease : A Single-Center, Randomized, Double-Blinded, Sham-Controlled, Parallel-Design, Investigator-Initiated Exploratory Clinical Trial
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD).
Participants will be randomly assigned to either an active rTMS group or a sham-control group.
The study aims to evaluate the efficacy and feasibility of a neuronavigation-guided bilateral M1 rTMS protocol.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Antidepressants and other psychotropic medications must have been stable for 4 weeks before baseline and remain unchanged during the study
At each clinical assessment, the time of the most recent dopaminergic medication dose and the participant's clinical medication state (ON or OFF) will be recorded. Whenever feasible, follow-up assessments will be performed at a similar time relative to the participant's usual dopaminergic medication schedule as at baseline.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Buk-gu
-
Daegu, Buk-gu, Coréia do Sul, 41404
- Kyungpook National University Chilgok Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Willing and able to provide written informed consent
- Male or female aged 40 to 90 years
- Diagnosed with Parkinson's disease with depressive symptoms
- Hoehn and Yahr stage 1 to 3
- On stable Parkinson's disease medication for at least 3 months prior to screening, with no planned dose increase during the study period
- Clinically significant depressive symptoms (BDI-II score ≥14) confirmed by clinician interview, without major psychiatric conditions that may confound their assessment
- Able to read and write Korean and capable of independently completing questionnaires
Exclusion Criteria:
- History of epilepsy
- Parkinson's disease caused by cerebrovascular disease, CNS infection, intoxication, or traumatic brain injury
- Diagnosed with Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies etc.)
- Clinically significant abnormal laboratory values (AST, ALT, or total bilirubin > 2.5 x ULN)
- Major psychiatric disorders other than depressive disorders (e.g., bipolar disorder, psychotic disorders) that may interfere with study participation or assessment of depressive symptoms
- Unable to follow instructions or communicate
- Pregnant, breastfeeding, or women of childbearing potential
- Febrile patients
- Patients with artificial hip joint implants
- Presence of conductive, ferromagnetic, or magnetically sensitive metal near the head or treatment coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils)
- Cardiac disease, especially patients with pacemakers
- Corrected or uncorrected visual acuity less than 0.5
- Use of drug infusion pumps or hearing aids
- Patients with acute illness
- Patients taking tricyclic antidepressants, neuroleptics, or other medications that may lower seizure threshold
- History of increased intracranial pressure or head trauma
- Evidence of external wounds on brain or neck
- Prominent psychotic symptoms other than depression (high NPI scores for hallucinations, delusions, mania)
- History of schizophrenia, bipolar disorder, or substance abuse
- Suicidal ideation (BDI-II item 9 score of 2 or 3)
- History of or planned deep brain stimulation or stereotactic surgery (pallidotomy, thalamotomy)
- Any participant deemed ineligible by the investigator, including those with medical conditions that may increase risk or interfere with study evaluation
- Currently enrolled in another clinical trial or used investigational drug/device within 30 days or 5 half-lives prior to consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Real rTMS
Participants receive active repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). Stimulation is delivered at 10 Hz, 90% of resting motor threshold (RMT), 1,000 pulses per session, once daily for 5 consecutive weekdays. Participants continue their existing Parkinson's disease medication throughout the study. |
High-frequency rTMS is delivered to bilateral primary motor cortex (M1) using neuronavigation guidance (BrainEyes). Parameters: 10 Hz, 90% of resting motor threshold (RMT), 50 pulses per train, 55-second inter-train interval, 20 trains per session, 1,000 pulses per session, once daily for 5 consecutive weekdays. |
|
Comparador Falso: Sham rTMS
Participants receive sham repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). The coil is tilted 90 degrees perpendicular to the scalp so that no magnetic field is delivered to the cortex. The same click sound and scalp sensation are maintained to preserve participant blinding. The session parameters are identical to the active rTMS group (10 Hz, 1,000 pulses per session, once daily for 5 consecutive weekdays). Participants continue their existing Parkinson's disease medication throughout the study. |
Sham rTMS is delivered with the coil tilted 90 degrees perpendicular to the scalp to prevent magnetic field delivery to the cortex. The same click sound and scalp sensation are maintained. Session parameters are identical to active rTMS group. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
The BDI-II is a 21-item self-reported questionnaire assessing the severity of depressive symptoms. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater severity of depressive symptoms. Changes in BDI-II total score from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2). |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change From Baseline in Neuropsychiatric Inventory (NPI) Scores
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
The NPI is a caregiver- or informant-based assessment of neuropsychiatric symptoms. It evaluates 12 neuropsychiatric symptom domains based on symptom frequency and severity. Changes in NPI scores from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2). |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Parkinson's Disease Questionnaire-39 (PDQ-39) Scores
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Disease-specific questionnaire assessing quality of life in Parkinson's disease patients across 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Scores range from 0 to 100; higher scores indicate worse quality of life. |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Comprehensive clinician-administered scale assessing motor and non-motor symptoms of Parkinson's disease across 6 subscales: non-motor experiences of daily living, motor experiences of daily living, motor examination, motor complications, Hoehn and Yahr staging, and Schwab and England ADL scale. Higher scores indicate greater disease severity. |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Parkinson's Disease Sleep Scale (PDSS) Scores
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Self-reported scale assessing sleep disturbances in Parkinson's disease patients, consisting of 15 items rated on a 5-point Likert scale (0-4). Covers three domains: nocturnal motor symptoms, PD-specific nocturnal symptoms, and sleep-specific disturbances. Higher scores indicate more frequent sleep disturbances. |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Toronto Alexithymia Scale-20 Korean Version (TAS-20-K) Scores
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Korean validated version of the Toronto Alexithymia Scale consisting of 20 items rated on a 5-point Likert scale, assessing three factors: difficulty identifying feelings (DIF), difficulty describing feelings (DDF), and externally oriented thinking (EOT). Higher total scores indicate greater alexithymia. |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Montreal Cognitive Assessment (MoCA) Scores
Prazo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Brief cognitive screening tool assessing multiple cognitive domains including attention, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores range from 0 to 30; higher scores indicate better cognitive function. |
Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Facial Expression Measures on FaceReader Analysis
Prazo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Automated facial expression analysis using FaceReader software to quantitatively assess facial action units (AUs) and emotional expression patterns. Participants perform facial emotion recognition and imitation tasks. Measures include response speed, latency, accuracy, and facial expression accuracy based on Action Unit analysis. |
Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Eye Movement Measures on Eye-Tracking
Prazo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Quantitative assessment of eye movements using screen-based Tobii Pro Spark. Measures include gaze speed, gaze position, gaze duration, gaze latency, and pupil size during task performance, providing objective evaluation of oculomotor function. |
Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Muscle Activity Measured by Electromyography (EMG)
Prazo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Muscle activity is measured using DELSYS Trigno Avanti Sensor and Trigno Quattro Sensor attached to the skin with medical tape. Wireless measurement technology enables free movement during task performance, with real-time data collection via dedicated software. |
Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Postural Stability and Balance Measures on BT4 Balance Assessment
Prazo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Quantitative assessment of postural stability using BT4 balance evaluation system, measuring center of pressure (COP) displacement during standing. Assesses limits of stability in anterior, posterior, and lateral directions, and COP movement during Romberg test under eyes-open and eyes-closed conditions. |
Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Body Composition Measured by Bioelectrical Impedance Analysis (InBody)
Prazo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Basic physical information is collected using InBody580 with 4-pole 8-point tactile electrode method. Bioelectrical impedance is measured across 3 frequency bands (5kHz, 50kHz, 250kHz) in 5 body segments (right arm, left arm, trunk, right leg, left leg), yielding 15 impedance measurements. |
Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Electrodermal Activity Measured by Galvanic Skin Response (GSR)
Prazo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Electrodermal activity is measured using the Shimmer Consensys GSR Development Kit, which records skin conductance changes between electrodes via wireless sensors. Sweat gland activation in response to internal or external stimuli alters skin moisture and ionic balance, producing measurable changes in electrodermal activity. |
Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
|
Change in Brain Structure and Connectivity on MRI
Prazo: Baseline and 1 week (±2 days) after the final stimulation session
|
Neuroimaging assessment of brain structure using MRI with two sequences: T1-weighted and T2-weighted structural imaging. Used to evaluate structural changes before and after rTMS treatment, and to guide neuronavigation-based TMS targeting. |
Baseline and 1 week (±2 days) after the final stimulation session
|
|
Change in Plasma Biomarker Concentrations
Prazo: Baseline and immediately after the final stimulation session
|
Quantitative measurement of candidate plasma biomarkers including Amyloid beta 40/42, Tau, phosphorylated Tau (p-Tau), and Neurofilament light chain (NfL) using antibody-based quantitative analysis methods (SIMOA, Luminex, or ELISA). |
Baseline and immediately after the final stimulation session
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Prazo: From the first stimulation session to the final stimulation session, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Safety will be assessed by the number and proportion of participants experiencing treatment-emergent adverse events (TEAEs) from the initiation of rTMS or sham stimulation through the final follow-up assessment. Adverse events will be summarized by event type, severity, and relationship to the investigational device. Serious adverse events, adverse device effects, and discontinuations due to adverse events will also be recorded and summarized by treatment group. |
From the first stimulation session to the final stimulation session, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Ho-Won Lee, MD, Kyungpook National University Chilgok Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Sinucleinopatias
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Processos Patológicos
- Sintomas Comportamentais
- Doenças Neurodegenerativas
- Distúrbios do Movimento
- Distúrbios parkinsonianos
- Doenças dos Gânglios da Base
- Condições Patológicas, Sinais e Sintomas
- Comportamento
- Depressão
- Doença de Parkinson
- Degeneração Nervosa
- Terapêutica
- Terapia de campo magnético
- Estimulação magnética transcraniana
Outros números de identificação do estudo
Outros números de identificação do estudo
- KNUCH 2025-08-046-006
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be publicly shared to protect the privacy of the participants. However, de-identified data may be available from the principal investigator upon reasonable request for research purposes, subject to institutional review board approval.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .